NCT03536208

Biological Effect of Warfarin on Pancreatic Cancer

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to asses the effect of warfarin on markers of AXL pathway in patients with pancreatic adenocarcinoma.

Detailed description

There is emerging evidence from pre-clinical models that Axl activation is critical for the tumorigenesis and metastasis of pancreatic cancer. Warfarin is a readily available drug in the clinical setting and could be easily, safely, and quickly used in patients in combination with known cytotoxic chemotherapies to improve overall survival. Oral warfarin has been well tolerated in both prophylaxis for catheter-associated thrombosis and in advanced pancreatic cancer patients. The aim of this trial is to confirm the preclinical evidence that warfarin affects AXL pathway in patients with pancreatic cancer. This will validate the effect of escalating doses of warfarin on circulating biomarkers of AXL.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Warfarin	5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.

Timeline

• Start date: 2019-05-15
• Primary completion: 2021-06-01
• Completion: 2022-06-01
• First posted: 2018-05-24
• Last updated: 2021-03-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study